En un nuevo estudio, unos científicos han identificado una diana terapéutica, hasta ahora desconocida, en uno de los cánceres hepáticos primarios más agresivos El estudio es obra de un equipo internacional liderado por investigadores de Universidad del Pa& …
Nueva diana terapéutica en uno de los cánceres hepáticos primarios más agresivos Read More »
The managed care giant raised its 2026 earnings outlook for the second time this year following the results, which its CFO called “fantastic.”
‘Back on track’: Centene swings to more than $1B in profit in Q2 Read More »
The plan involves transferring production lines and cutting jobs, following a slowdown in two of the company’s key product lines.
Boston Scientific to restructure, taking up to $800M in charges Read More »
The company recovered 186 million euros after it “largely completed the U.S. tariff refund process” in the quarter, CEO Roy Jakobs said on an earnings call.
Philips largely recoups struck-down Trump tariffs in Q2 Read More »
As GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.
GSK shares rise as $2.5B cost-cutting plan unveiled Read More »
El equipo editorial de Pokeriomokykla sigue de cerca cómo las plataformas digitales que operan en España compiten en fiabilidad técnica y en capacidad de procesar datos en tiempo real. Desde esa perspectiva, la precisión demostrada por Copernicus durante los inc …
The FDA’s rebuff of Replimune comes a day after the agency similarly called into question the Phase 3 trial for Capricor’s Duchenne muscular dystrophy cell therapy.
En los últimos dos años se ha anunciado una oleada de dispositivos wearables con inteligencia artificial que prometían cambiar por completo la forma en que interactuamos con la tecnología. Pines que escuchan y responden como un asistente personal, colgantes que recuerdan …
Wearables con IA en España: qué pueden hacer realmente Read More »
Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics in this space.
Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study Read More »
Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow Read More »
